Emerging Markets Clinical Trials

BRIC Countries Report

Emerging Markets Clinical Trials

$995.00

Emerging markets clinical trials in BRIC are the next frontier of global industry expansion.  As this expansion makes its home in Brazil, Russia, India and China (BRIC), imagine the impact of a patient pool that numbers 3 billion: an immediate cure for patient shortages (or recruitment challenges) that plague studies in North America and Western Europe, unparalleled access to untapped patient populations, and new opportunities to meet the growing medical needs of these countries.

Confidently tap into the potential of the BRIC markets, fulfill protocol, and ultimately, realize significant cost and time savings. Expand your understanding of BRIC, individually and as a whole, using rankings data and best practices found in this report.

  • Description
  • Additional information

REPORT HIGHLIGHTS

Emerging Markets Clinical Trials: BRIC Countries Report

  • Publication Date: November 2010
  • Pages: 275
  • Chapters: 4
  • Metrics: 500+
  • Charts/Graphics: 150+
  • Profiles: 23
Report Features

The next frontier of global industry expansion makes its home in Brazil, Russia, India and China (BRIC). Imagine the impact of a patient pool that numbers 3 billion — an immediate cure for patient shortages (or recruitment challenges) that plague studies in North America and Western Europe, unparalleled access to untapped patient populations, and new opportunities to meet the growing medical needs of these countries.Confi dently tap into the potential of the BRIC markets, fulfi ll protocol, and ultimately,
realize significant cost and time savings.

Reason to Buy

Eliminate confusion about emerging markets clinical trials BRIC by weighing the advantages and drawbacks of different countries and examine rankings for 13 clinical factors to enable strategic decision-making. Gain quick access to relevant demographics and economics information for a comprehensive analysis of the clinical environment. Learn from top executives’ firsthand experiences — both successes and misfires. Recommendations show your team how to improve CRO selection, management and oversight, and more. Explore 23 in-depth profiles and find one that matches your company’s situation.

Target Audience

Executives, directors, and managers involved in the following areas should consider purchasing this report:
– Clinical development
– Site/Trial Management
– Patient Recruitment
– Strategic planning groups
– Contract Research Organizations (CROs)
– Strategic Planning

Chapter Example

Even before the economy faltered and the patent cliff approached, the life sciences industry turned to the emerging markets — not to save revenue streams, but to enable them. With tens of thousands of ongoing trials in the United States and Western Europe, companies find it harder and harder to meet the patient enrollment numbers necessary to give a brand a shot at approval. The blame for this issue has been placed on everyone from the FDA and EMEA (for impossible-to-meet protocols) to physicians (for over-medicating potential patients) to patients (for not caring about research) to the companies themselves for running too many trials, many of which will not end in groundbreaking results.